

Anti-EphA3 Antibody (Ifabotuzumab)

Introduction

Ifabotuzumab (KB004) is an IgG1κ antibody (KD=610 pM) targeting EphA3. Ifabotuzumab can induce tumor cell apoptosis and activate antibody-dependent cell-mediated cytotoxicity (ADCC), destroying tumor vasculature. Ifabotuzumab can reduce human idiopathic pulmonary fibrosis (IPF) CCR10+ cells and improve lung fibrosis.

Product parameters

Alternative Names	KB004, IIIA4, fibatuzumab
Target Accession	P29320
Target	EphA3
CAS number	1234137-51-9
Molecular Weight	145.4 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

